Especially within phase one programs, sometimes we struggle to give the right patient with a specific molecular alteration the right trial. The reason is that maybe the trial is not open at the time the patient needs it, or that molecular alteration is so rare that we cannot identify the right patient for the trial. So in the future, we will have different tools to have an AI-enabled trial match...
Especially within phase one programs, sometimes we struggle to give the right patient with a specific molecular alteration the right trial. The reason is that maybe the trial is not open at the time the patient needs it, or that molecular alteration is so rare that we cannot identify the right patient for the trial. So in the future, we will have different tools to have an AI-enabled trial match. For example, there are companies like Tempus, which already routinely screen patients molecularly and then can recognize which study might be an opportunity for the specific patients. And the next step will be accessibility. So if a patient is very far away, in the future, we might be able to open studies in a much shorter time, considering that now it will take at least six months in a good scenario, but the idea is to do really fast-approaching clinical trials with a similar time frame of a few days, like 10 days, so that would be amazing and will improve substantially the quality of life of the patient, who might receive their treatment in a center, a referral center, of course, but in proximity to their home.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
